Faecal lactoferrin, calprotectin, pmn-elastase, crp, and white blood cell count as indicators for mucosal healing and clinical course of disease in patients with mild to moderate ulcerative colitis: Post hoc analysis of a prospective clinical trial

Journal of Crohn's and Colitis

Volumn 10, Issue 7, 2016, Pages 786-794

  Langhorst, Jost ^a,b   Boone, James ^c   Lauche, Romy ^b   Rueffer, Andreas ^d   Dobos, Gustav ^b  

^a KLINIKEN ESSEN MITTE   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c Techlab   (United States)

^d Enterosan Labor L+S   (Germany)

Author keywords

Calprotectin; CRP; Faecal lactoferrin; Monitoring; Mucosal healing; PMN elastase; Relapse; Ulcerative colitis; White blood cell count

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; CHAMOMILE; COFFEE CHARCOAL; HERBACEOUS AGENT; LACTOFERRIN; LEUKOCYTE ELASTASE; MESALAZINE; MYRRH; UNCLASSIFIED DRUG; LTF PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL ACTIVITY INDEX; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; ENDOSCOPIC INDEX; FECES; FEMALE; GASTROINTESTINAL ENDOSCOPY; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REMISSION; SENSITIVITY AND SPECIFICITY; UC DISEASE ACTIVITY INDEX; ULCER HEALING; ULCERATIVE COLITIS; CHEMISTRY; COLITIS, ULCERATIVE; DIAGNOSTIC IMAGING; FOLLOW UP; INTESTINE MUCOSA; METABOLISM; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SIGMOIDOSCOPY; WOUND HEALING;

ADULT; AGED; BIOMARKERS; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; DISEASE PROGRESSION; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTESTINAL MUCOSA; LACTOFERRIN; LEUKOCYTE COUNT; LEUKOCYTE ELASTASE; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SIGMOIDOSCOPY; WOUND HEALING;

EID: 85012225969     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjw044     Document Type: Article

References (48)

1. Langhorst J, Elsenbruch S, Kolzer J, Rueffer A, Michalsen A, Dobos GJ. Non-invasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: Performance of fecal Lactoferrin, Calprotectin and PMN-Elastase, CRP, and clinical indices. Am J Gastroenterol 2008;103:162-9.
2. Travis SP, Higgins PD, Orchard T, et al. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther 2011;34:113-24.
3. Cooney RM, Warren BF, Altman DG, Abreu MT, Travis SP. Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials 2007;8:17-22
4. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763-86.
5. Rachmilewitz D. Coated mesalazine [5-aminosalicylic acid] versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989;298:82-6.
6. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92:1894-8.
7. Higgins PD, Schwartz M, Mapili J, Krokos I, Leung J, Zimmermann EM. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005;54:782-8.
8. Kiesslich R, Jung M, Galle PR, Neurath MF. Ulcerative colitis-how can endoscopic observation be improved? Dtsch Med Wochenschr 2003;128:139-41.
9. Fiocca R, Ceppa P. The diagnostic reliability of endoscopic biopsies in diagnosis colitis. J Clin Pathol 2003;56:321-2.
10. Kane S, Lu F, Kornbluth A, Awais D, Higgins PD. Controversies in mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2009;15:796-800.
11. Fiorino G, Cesarini M, Indriolo A, Malesci A. Mucosal healing in ulcerative colitis: where do we stand? Curr Drug Targets 2011;12:1417-23.
12. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001;120:13-20.
13. Dave M, Loftus EV Jr. Mucosal healing in inflammatory bowel disease-a true paradigm of success? Gastroenterol Hepatol 2012;8:29-38.
14. Froslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian populationbased cohort. Gastroenterology 2007;133:412-22.
15. Eckardt VF, Gaedertz C, Eidner C. Colonic perforation with endoscopic biopsy. Gastrointest Endosc 1997;6:560-2.
16. Ristvedt SL, McFarland EG, Weinstock LB, Thyssen EP. Patient preferences for CT colonography, conventional colonoscopy, and bowel preparation. Am J Gastroenterol 2003;3:578-85.
17. Langhorst J, Kuehle C, Nuefer M, et al. MR colonography without bowel purgation for the assessment of inflammatory bowel diseases: diagnostic accuracy and patients' acceptance. Inflamm Bowel Dis 2007;8:1001-8.
18. Vermeire S, Van Assche G, Rutgeerts P. Laboratory Markers in IBD: Useful, Magic, or unnecessary toys? Gut 2006;55:426-31
19. Kopylov U, Rosen G, Bressler B, et al. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis 2014;4:742-56.
20. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011;1400:1817-26.
21. Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther 2007;25:247-55.
22. Langhorst J, Elsenbruch S, Mueller T, et al. Comparison of 4 Neutrophilderived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis 2005:11:1085-91.
23. Langhorst J, Varnhagen I, Schneider SB. et al. Randomised Clinical Trial: A Herbal Preparation of Myrrh, Chamomile and Coffee Charcoal compared with Mesalazine in Maintaining Remission in Ulcerative Colitis-a double-blind, double Dummy Study. Aliment Pharmac Ther 2013;38:490-500.
24. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis: current management. J Crohns Colitis 2012;:991-1030.
25. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194-201.
26. Rutgeerts P, Van Assche G, Sandborn WJ, et al.; EXTEND Investigators. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012;142:1102-11
27. Langhorst J, Hofstetter A, Wolfe F, Hauser W. Short term stress, but not mucosal healing nor depression was predictive for the risk of relapse in patients with ulcerative colitis in clinical remission: A prospective 12-months follow-up study. Inflammat Bowel Dis 2013;19:2380-6.
28. Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011;9:483-9.
29. Sipponen T, Karkkainen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008;15:28:1221-9.
30. Zhou XL, Xu W, Tang XX, et al. Fecal lactoferrin in discriminating inflammatory bowel disease from Irritable bowel syndrome: a diagnostic metaanalysis. BMC Gastroenterol 2014;14:121.
31. von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007;102:803-13.
32. Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002;123:450-60.
33. Tibble JA, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol 2001;7:460-5.
34. Gisbert JP, Bermejo F, Perez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009;15:1190-8.
35. Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003;98:1309-14.
36. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: A predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004;39:1017-20.
37. Xiang JY, Ouyang Q, Li GD, et al. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol 2008;14:53-7.
38. Saitoh O, Sugi K, Matsuse R, et al. The forms and the levels of fecal PMN-elastase in patients with colorectal diseases. Am J Gastroenterol 1995;90:388-93.
39. Andus T, Gross V, Caesar I, et al. PMN-elastase in assessment of patients with inflammatory bowel disease. Dig Dis Sci 1993;38:1638-44.
40. Adeyemi EO, Hodgson HJ. Faecal elastase reflects disease activity in active ulcerative colitis. Scand J Gastroenterol 1992;27:139-42.
41. Sugi K, Saitoh O, Hirata I, et al. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: Comparison with other neutrophil-derived proteins. Am J Gastroenterol 1996;91:927-34.
42. Langhorst J, Boone J. Fecal Lactoferrin as Non-Invasive Biomarker in Inflammatory Bowel Disease. Drugs Of Today 2012;48:149-61.
43. Lin JF, Chen JM, Zuo JH, et al. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis 2014;20:1407-15.
44. Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis 2012 Oct;18:1894-9.
45. Rogler G, Aldeguer X, Kruis W, et al. Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion. J Crohns Colitis 2013;7:670-7.
46. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis 2013;19:332-41.
47. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009;15:1851-8.
48. Meucci G, Vecchi M, Astegiano M, et al. The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali [GSMII]. Am J Gastroenterol 2000;95:469-73.